From: Phase II placebo-controlled study of nepafenac ophthalmic suspension 0.1% for postoperative inflammation and ocular pain associated with cataract surgery in Japanese patients
Treatment
Total
Day 1
Day 3
Day 7
Day 14
N
%
Nepafenac group
106
2
1.9
Placebo group
105
0
0.0
1
1.0
9
8.6
P value
0.5467
0.3974
0.2001
0.2236